Ryan J. Watts - 16 Jun 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
President and CEO, Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
16 Jun 2023
Transactions value $
-$1,536,000
Form type
4
Filing time
20 Jun 2023, 18:28:02 UTC
Previous filing
24 Apr 2023
Next filing
14 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Options Exercise $34,000 +50,000 +2.23% $0.68* 2,289,913 16 Jun 2023 See footnote F1
transaction DNLI Common Stock Sale -$1,570,000 -50,000 -2.18% $31.4 2,239,913 16 Jun 2023 See footnote F1, F2
holding DNLI Common Stock 188,437 16 Jun 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -50,000 -4.27% $0 1,120,617 16 Jun 2023 Common Stock 50,000 $0.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F2 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted February 10, 2023.
F3 Includes 188,437 RSUs.
F4 The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.